A study investigating the CD7 expression levels on CD34+/CD38− leukemic blast cells in the BM samples of 236 AML patients concluded that CD7 was aberrantly expressed in 43% of the investigated cases. This evidence concerns the gene CD7 and acute myeloid leukemia.